By Ben Glickman
Shares of Cytokinetics rose after the company said it expected topline results from its aficamten heart drug trial by the end of the year.
The stock was up 11% to $30.50 in Friday trading. Shares have fallen 33% this year.
The South San Francisco-based biopharmaceutical company released the baseline characteristics of patients in Sequoia-HCM, a Phase 3 trial of aficamten in patients with hypertrophic cardiomyopathy.
The trial is evaluating aficamten, a cardiac myosin inhibitor, in patients with symptomatic obstructive HCM who receive background medical therapy and has enrolled 282 patients.
HCM is a disease that causes patients’ heart muscles to become thicker, which can limit heart function and ability to exercise.
Write to Ben Glickman at [email protected]
Read the full article here